drugset / Trial / NCT01090310
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
RandomizedParallel-groupTriple-blindTreatment
Summary
This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression
Timeline
- Start
- 2010-08
- Primary completion
- 2011-07
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Secukinumab | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | Secukinumab | Monoclonal antibody | 300 mg | Subcutaneous |